Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours

Endocrine-Related Cancer

Volumn 18, Issue SUPPL. 1, 2011, Pages

  Khan, Mohid S ^a   Caplin, Martyn E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; (DOTA PHENYLALANINE TYROSINE 3)OCTREOTATE LU 177; ALPHA INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYPROHEPTADINE; DIAZOXIDE; DOTA LANREOTIDE Y 90; DOTATOC Y 90; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; HISTAMINE H2 RECEPTOR ANTAGONIST; HUMAN INTERFERON; IRINOTECAN; OCTREOTIDE; PEGINTERFERON; PROTON PUMP INHIBITOR; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ABDOMINAL SURGERY; ABLATION THERAPY; APPENDECTOMY; APPENDIX TUMOR; ARTICLE; BINDING AFFINITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CHEMOEMBOLIZATION; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON RESECTION; COLORECTAL TUMOR; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM TUMOR; DIZZINESS; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG TOLERABILITY; EMERGENCY SURGERY; ENDOCRINE SURGERY; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FLUID THERAPY; GALLBLADDER DISEASE; GALLSTONE; GASTRINOMA; GASTROENTEROPANCREAS NEUROENDOCRINE TUMOR; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TRACT SCINTISCANNING; GLUCAGONOMA; HEMICOLECTOMY; HIRSUTISM; HUMAN; HYPERGASTRINEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULINOMA; LAPAROTOMY; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; LYMPHATIC DRAINAGE; MALABSORPTION; MENTAL DISEASE; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS ISLET CELL CARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PARAGANGLIOMA; PERIOPERATIVE PERIOD; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHYDRATION; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CARCINOID; SURGICAL APPROACH; THYROID DISEASE; THYROID MEDULLARY CARCINOMA; VERNER MORRISON SYNDROME; ZOLLINGER ELLISON SYNDROME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RADIOISOTOPES; RECEPTORS, PEPTIDE; SOMATOSTATIN; TOR SERINE-THREONINE KINASES;

EID: 80054799657     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0271     Document Type: Article

References (178)

1. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K & Curley SA 2004 Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Annals of Surgery 239 818-825. (doi:10.1097/01.sla.0000128305.90650. 71)
2. Ahlman H 1999 Surgical treatment of carcinoid tumours of the stomach and small intestine. Italian Journal of Gastroenterology and Hepatology 31 (Suppl 2) S198-S201. (Pubitemid 29527895)
3. Ahlman H 2006 Malignant pheochromocytoma: state of the field with future projections. Annals of the New York Academy of Sciences 1073 449-464. (doi:10.1196/annals.1353.049)
4. Ahlman H, Wangberg B, Jansson S, Friman S, Olausson M, Tylen U & Nilsson O 2000 Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 62 (Suppl 1) 59-68. (doi:10.1159/000051857)
5. Ahlman H, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B & Olausson M 2004 Liver transplantation for treatment of metastatic neuroendocrine tumors. Annals of the New York Academy of Sciences 1014 265-269. (doi:10.1196/annals.1294.029)
6. Anthuber M, Jauch KW, Briegel J, Groh J & Schildberg FW 1996 Results of liver transplantation for gastroenteropancreatic tumor metastases. World Journal of Surgery 20 73-76. (doi:10.1007/s002689900013)
7. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De BT, Mitry E, Schlumberger M & Rougier P 2001 Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. European Journal of Cancer 37 1014-1019. (doi:10.1016/S0959-8049(01)00073-9)
8. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R et al. 2005 Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clinical Gastroenterology and Hepatology 3 761-771. (doi:10.1016/S1542- 3565(05)00481-7)
9. Arnold PM, Floyd HE, Anderson KK & Newell KL 2010 Surgical management of carcinoid tumors metastatic to the spine: report of three cases. Clinical Neurology and Neurosurgery 112 443-445. (doi:10.1016/j.clineuro.2010.01.008)
10. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di BM, Buzzoni R, Celio L, Vitali M et al. 2002 Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Annals of Oncology 13 614-621. (doi:10.1093/annonc/mdf064)
11. Bajetta E, Procopio G, Catena L, Martinetti A, De DS, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G et al. 2006 Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer 107 2474-2481. (doi:10.1002/cncr.22272)
12. Bak M & Jorgensen LJ 1987 Adenocarcinoid of the appendix presenting with metastases to the liver. Diseases of the Colon and Rectum 30 112-115. (doi:10.1007/BF02554947)
13. Baum RP, Söldner J, Schmucking M & Niesen A 2003 Intravenous and intra-arterial peptide receptor radionuclidetherapy (PRRT) using Y90-DOTA-Tyr3-octreotate (DOTATATE) in patients with metastatic neuroendocrine tumours. European Journal of Nuclear Medicine 44 S238.
14. Bax ND, Woods HF, Batchelor A & Jennings M 1996 Octreotide therapy in carcinoid disease. Anticancer Drugs 7 (Suppl 1) 17-22. (doi:10.1097/00001813- 199601001-00004)
15. Berber E, Flesher N & Siperstein AE 2002 Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World Journal of Surgery 26 985-990. (doi:10.1007/s00268-002-6629-5)
16. Blonski WC, Reddy KR, Shaked A, Siegelman E & Metz DC 2005 Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature. World Journal of Gastroenterology 11 7676-7683.
17. 90Y-DOTATOC in association with amino acid infusion: a phase I study. European Journal of Nuclear Medicine and Molecular Imaging 30 207-216. (doi:10.1007/s00259-002-1023-y)
18. 131I-metaiodobenzylguanidine. Nuclear Medicine Communications 14 856-861. (doi:10.1097/00006231-199310000-00004)
19. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, Sempoux C, Goffette P, Ciccarelli O, Borbath I, Hubert C, Gigot JF, Hassoun Z et al. 2010 Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transplant International 23 668-678. (doi:10.1111/j.1432-2277.2010.01086.x)
20. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G &Grimelius L 2005 Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Annals of Surgery 242 64-73. (doi:10.1097/01.sla. 0000167862.52309.7d)
21. Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y & Blumgart LH 1999 Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. Journal of Vascular and Interventional Radiology 10 397-403. (doi:10.1016/S1051-0443(99)70055-2)
22. Buchanan KD, Collins JS, Varghese A, Johnston CF & Shaw C 1990 Sandostatin and the Belfast experience. Digestion 45 (Suppl 1) 11-14. (doi:10.1159/000200255)
23. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B & Costanzi JH 1987a A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60 2891-2895. (doi:10.1002/1097-0142(19871215)60:12〈2891::AID- CNCR2820601207〉3.0.CO;2-6)
24. Bukowski RM, Theodors A, Purvis JD, Budd GT, Weick JK & Gahbauer R 1987b Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma. A Southwest Oncology Group Pilot Study. American Journal of Clinical Oncology 10 376-379. (doi:10.1097/00000421- 198710000-00002)
25. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y & Blumgart LH 2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of the American College of Surgeons 190 432-445. (doi:10.1016/S1072-7515(00)00222-2)
26. Chen H, Hardacre JM, Uzar A, Cameron JL & Choti MA 1998 Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? Journal of the American College of Surgeons 187 88-92. (doi:10.1016/S1072- 7515(98)00099-4)
27. Cheng PN & Saltz LB 1999 Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 944-948. (doi:10.1002/(SICI)1097- 0142(19990915)86:6〈944::AID-CNCR8〉3.0.CO;2-P)
28. Clouse ME, Perry L, Stuart K & Stokes KR 1994 Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55 (Suppl 3) 92-97. (doi:10.1159/000201208)
29. Coppa J, Pulvirenti A, Schiavo M, Romito R, Collini P, Di BM, Fabbri A, Regalia E & Mazzaferro V 2001 Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplantation Proceedings 33 1537-1539. (doi:10.1016/S0041-1345(00)02586-0)
30. Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K & Walecki J 2010 Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology 21 787-794. (doi:10.1093/annonc/mdp372)
31. 90Y-DOTATOC. European Journal of Nuclear Medicine 28 1552-1554. (doi:10.1007/s002590100599)
32. Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P et al. 2004 The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? European Journal of Cancer 40 515-520. (doi:10.1016/j.ejca.2003.09.035)
33. Detjen KM, Welzel M, Farwig K, Brembeck FH, Kaiser A, Riecken EO, Wiedenmann B & Rosewicz S 2000 Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 118 735-748. (doi:10.1016/S0016-5085(00)70143-0)
34. Detjen KM, Kehrberger JP, Drost A, Rabien A, Welzel M, Wiedenmann B & Rosewicz S 2002 Interferon-gamma inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. International Journal of Oncology 21 1133-1140.
35. Dirix LY, Vermeulen PB, Fierens H, De SB, Corthouts B &Van Oosterom AT 1996 Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors - an antiangiogenic effect? Anticancer Drugs 7 175-181. (doi:10.1097/00001813- 199603000-00005)
36. Doberauer C, Mengelkoch B, Kloke O, Wandl U & Niederle N 1991 Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Acta Oncologica 30 603-605. (doi:10.3109/ 02841869109092426)
37. Dominguez S, Denys A, Menu Y & Ruszniewski P 1999 Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Italian Journal of Gastroenterology and Hepatology 31 (Suppl 2) S213-S215. (Pubitemid 29527898)
38. Dominguez S, Denys A, Madeira I, Hammel P, Vilgrain V, Menu Y, Bernades P & Ruszniewski P 2000 Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. European Journal of Gastroenterology & Hepatology 12 151-157. (doi:10.1097/00042737-200012020- 00004)
39. Dougherty TB & Cronau LH Jr 1998 Anesthetic implications for surgical patients with endocrine tumors. International Anesthesiology Clinics 36 31-44. (doi:10.1097/00004311-199803630-00006)
40. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D &Chapuis Y 1996 Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World Journal of Surgery 20 908-914. (doi:10.1007/ s002689900138)
41. Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK Jr, Chapman WC, Webb L, Mazer M, Meranze S &Pinson CW 1998 Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. American Journal of Surgery 175 408-412. (doi:10.1016/S0002-9610(98)00042-7)
42. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer 95 1148-1154. (doi:10.1038/sj.bjc.6603419)
43. Duran-Prado M, Malagon MM, Gracia-Navarro F & Castano JP 2008 Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Molecular and Cellular Endocrinology 286 63-68. (doi:10.1016/j.mce.2007.12.006)
44. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M et al. 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research 13 2986-2991. (doi:10.1158/1078-0432.CCR-06-2053)
45. Eledrisi MS, Stuart CA & Alshanti M 2002 Insulinoma in a patient with tuberous sclerosis: is there an association? Endocrine Practice 8 109-112. (Pubitemid 34248088)
46. Engstrom PF, Lavin PT, Moertel CG, Folsch E & Douglass HO Jr 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology 2 1255-1259. (Pubitemid 15202700)
47. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E &Oberg K 1990 Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65 1883-1890. (doi:10.1002/1097- 0142(19900501)65:9〈1883::AID-CNCR2820650902〉3.0.CO;2-3)
48. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE & Oberg KE 1998 Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 2293-2301. (doi:10.1002/(SICI)1097- 0142(19981201)83:11〈2293::AID-CNCR8〈3.0.CO;2-E)
49. Eriksson B, Kloppel G, Krenning E, Ahlman H, Plockinger U, Wiedenmann B, Arnold R, Auernhammer C, Korner M, Rindi G et al. 2008 Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87 8-19. (doi:10.1159/000111034)
50. 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. European Journal of Nuclear Medicine and Molecular Imaging 34 1219-1227. (doi:10.1007/s00259-006-0355-4)
51. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO & Wiedenmann B 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689-2696. (doi:10.1200/JCO.2003.12.142)
52. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C & Schwartz M 2004 Liver transplantation for neuroendocrine tumors. Journal of Gastrointestinal Surgery 8 208-212. (doi:10.1016/j.gassur. 2003.11.010)
53. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C & Arnold R 1999 Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. American Journal of Gastroenterology 94 1381-1387. (doi:10.1111/j.1572-0241.1999.01090.x)
54. Frilling A, Rogiers X, Malago M, Liedke O, Kaun M &Broelsch CE 1998 Liver transplantation in patients with liver metastases of neuroendocrine tumors. Transplantation Proceedings 30 3298-3300. (doi:10.1016/S0041-1345(98) 01037-9)
55. Frilling A, Malago M, Weber F, Paul A, Nadalin S, Sotiropoulos GC, Cicinnati V, Beckebaum S, Bockisch A, Mueller-Brand J et al. 2006 Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transplantation 12 1089-1096. (doi:10.1002/lt.20755)
56. Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, Reynolds N & Caplin ME 2003 Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Alimentary Pharmacology & Therapeutics 17 437-444. (doi:10.1046/j.1365-2036.2003.01420.x)
57. Gillams A, Cassoni A, Conway G & Lees W 2005 Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdominal Imaging 30 435-441. (doi:10.1007/s00261-004-0258-4)
58. Goede AC & Winslet MC 2003 Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Disease 5 123-128. (doi:10.1046/j.1463-1318. 2003.00457.x)
59. Gullo L 1996 Somatostatin analogues and exocrine pancreatic secretion. Digestion 57 (Suppl 1) 93. (doi:10.1159/000201408)
60. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van MG, De TN & Stupp R 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Research 10 1871-1874. (doi:10.1158/1078-0432.CCR-03-0384)
61. Hobday TJ, Rubin J, Holen J, Picus R, Donehower R, Marschke W, Maples R, Lloyd M, Mahoney C &Erlichman C 2007 MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. Journal of Clinical Oncology 25 4504. (doi:10.1200/JCO.2007.12.3901)
62. Hou Z, Elasmar R, Lozano P, Hoff R & Wolff J 2011 A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proceedings of the American Society of Clinical Oncology 22 abstract 1508.
63. Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E, Vatn MH & Bergan A 1995 Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scandinavian Journal of Gastroenterology 30 789-796. (doi:10.3109/00365529509096329)
64. Jaeck D, Oussoultzoglou E, Bachellier P, Lemarque P, Weber JC, Nakano H & Wolf P 2001 Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World Journal of Surgery 25 689-692. (doi:10.1007/s00268-001-0014-7)
65. Janson ET, Ronnblom L, Ahlstrom H, Grander D, Alm G, Einhorn S & Oberg K 1992 Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Annals of Oncology 3 635-638.
66. de Jong M, Breeman WA, Bernard HF, Kooij PP, Slooter GD, van Eijck CH, Kwekkeboom DJ, Valkema R, Macke HR & Krenning EP 1999 Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Quarterly Journal of Nuclear Medicine 43 356-366. (Pubitemid 30113564)
67. Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H, Gress TM, Arnold R, Klose KJ & Wagner HJ 2009 Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79 137-142. (doi:10.1159/000209849)
68. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Levy P, Vilgrain V, Ruszniewski P & Belghiti J 2008 Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Annals of Surgery 247 659-665. (doi:10.1097/SLA.0b013e31816a7061)
69. Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M &Modlin I 2008 Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 113 690-700. (doi:10.1002/cncr.23700)
70. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V & Wallace S 1999 Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Investigation 17 474-478. (doi:10.3109/07357909909032856)
71. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W &Morris DL 2008 Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 921-929. (doi:10.1002/cncr.23685)
72. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R & Yao JC 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 4762-4771. (doi:10.1200/JCO.2004.04.024)
73. Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, De Herder WW, van Eijck CH, Kwekkeboom DJ, de Jong M, Jamar F et al. 2000 The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results in Cancer Research 153 1-13.
74. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y & Arnold R 2002 Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50 52-60. (doi:10.1136/gut.50.1.52)
75. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C &Fuchs CS 2006 A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology. ASCO Annual Meeting Proceedings Part 1 24 18S 4044.
76. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 26 3403-3410. (doi:10.1200/JCO.2007.15.9020)
77. Kvols LK, Martin JK, Marsh HM & Moertel CG 1985 Rapid reversal of carcinoid crisis with a somatostatin analogue. New England Journal of Medicine 313 1229-1230. (Pubitemid 16205347)
78. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J &Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315 663-666. (doi:10.1056/NEJM198609113151102)
79. Kvols L, Glusman E, Hahn EA, Öberg K, Anthony L, O'Dorisio TM, De Herder W, Darby CH, McBride K & Wiedenmann B 2007 The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide. Journal of Clinical Oncology 25 4558 (C131).
80. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL & Krenning EP 2005 Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology 23 2754-2762. (doi:10.1200/JCO.2005.08.066)
81. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO &Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130. (doi:10.1200/JCO.2007.15. 2553)
82. Lehnert T & Knaebel HP 1997 Diagnosis and therapy of liver metastases of neuroendocrine tumors. Chirurg 68 122-131. (doi:10.1007/s001040050161)
83. Lemmer K, Ahnert-Hilger G, Hopfner M, Hoegerle S, Faiss S, Grabowski P, Jockers-Scherubl M, Riecken EO, ZeitzM&Scherubl H 2002 Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sciences 71 667-678. (doi:10.1016/S0024-3205(02)01703-4)
84. Makridis C, Oberg K, Juhlin C, Rastad J, Johansson H, Lorelius LE & Akerstrom G 1990 Surgical treatment of mid-gut carcinoid tumors. World Journal of Surgery 14 377-383. (doi:10.1007/BF01658532)
85. Marrache F, Vullierme MP, Roy C, El AY, Couvelard A, O'Toole D, Mitry E, Hentic O, Hammel P, Levy P et al. 2007 Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. British Journal of Cancer 96 49-55. (doi:10.1038/sj.bjc. 6603526)
86. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S & Fuchs CS 2004 Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. American Journal of Clinical Oncology 27 485-488. (doi:10.1097/01.coc.0000135343.06038.eb)
87. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P et al. 1999 Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer 81 1351-1355. (doi:10.1038/sj.bjc.6690325)
88. Modlin IM, Shapiro MD & Kidd M 2004 Carcinoid tumors and fibrosis: an association with no explanation. American Journal of Gastroenterology 99 2466-2478. (doi:10.1111/j.1572-0241.2004.40507.x)
89. Modlin IM, Pavel M, Kidd M & Gustafsson BI 2010 Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology & Therapeutics 31 169-188. (doi:10.1111/j.1365-2036.2009.04174.x)
90. Moertel CG & Hanley JA 1979 Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials 2 327-334. (Pubitemid 10021790)
91. Moertel CG, Hanley JA & Johnson LA 1980 Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 303 1189-1194. (doi:10.1056/ NEJM198011203032101)
92. Moertel CG, Weiland LH, Nagorney DM & Dockerty MB 1987 Carcinoid tumor of the appendix: treatment and prognosis. New England Journal of Medicine 317 1699-1701. (doi:10.1056/NEJM198712313172704)
93. Moertel CG, Rubin J & Kvols LK 1989 Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. Journal of Clinical Oncology 7 865-868. (Pubitemid 19172459)
94. Moertel CG, Kvols LK, O'Connell MJ & Rubin J 1991a Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 227-232. (doi:10.1002/1097-0142(19910715)68:2〈227::AID- CNCR2820680202〉3.0.CO;2-I)
95. Moertel CG, Kvols LK & Rubin J 1991b A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67 33-36. (doi:10.1002/1097-0142(19910101)67:1〈33::AID- CNCR2820670107〉3.0.CO;2-E)
96. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG & Klaassen D 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326 519-523. (doi:10.1056/NEJM199202203260804)
97. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP et al. 2001 Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical Endocrinology 55 47-60. (doi:10.1046/j.1365-2265.2001.01309.x)
98. Nave H, Mossinger E, Feist H, Lang H & Raab H 2001 Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 129 170-175. (doi:10.1067/msy.2001.110426)
99. Nikou GC, Toubanakis C, Nikolaou P, Giannatou E, Safioleas M, Mallas E & Polyzos A 2005 VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 52 1259-1265. (Pubitemid 40942228)
100. Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William-Olsson L, Fjalling M, Forssell-Aronsson E &Ahlman H 1998 Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. British Journal of Cancer 77 632-637. (doi:10.1038/bjc.1998.101)
101. Norlen O, Hessman O, Stalberg P, Akerstrom G & Hellman P 2010 Prophylactic cholecystectomy in midgut carcinoid patients. World Journal of Surgery 34 1361-1367. (doi:10.1007/s00268-010-0428-1)
102. Norton JA, Kivlen M, Li M, Schneider D, Chuter T & Jensen RT 2003 Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Archives of Surgery 138 859-866. (doi:10.1001/archsurg. 138.8.859)
103. Oberg K 2000 Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 (Suppl 1) 92-97. (Pubitemid 30665946)
104. Oberg K & Eriksson B 1991 The role of interferons in the management of carcinoid tumors. Acta Oncologica 30 519-522. (doi:10.3109/02841869109092411)
105. Oberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L, Jonsdottir B, Magnusson A & Wilander E 1986 Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treatment Reports 70 1297-1304. (Pubitemid 17184294)
106. Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L & Wilander E 1989 Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. Journal of the National Cancer Institute 81 531-535. (doi:10.1093/jnci/81.7.531)
107. Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B &Plockinger U 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 90 209-213. (doi:10.1159/000183751)
108. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, Wangberg B & Ahlman H 2007 Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transplantation 13 327-333. (doi:10.1002/lt.21056)
109. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, Blumberg J & Ruszniewski P 2000 Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88 770-776. (doi:10.1002/(SICI) 1097-0142(20000215)88:4〈770::AID-CNCR6〉3.0.CO;2-0)
110. O'Toole D, Maire F & Ruszniewski P 2003 Ablative therapies for liver metastases of digestive endocrine tumours. Endocrine-Related Cancer 10 463-468. (doi:10.1677/erc.0.0100463)
111. O'Toole D, Hentic O, Corcos O & Ruszniewski P 2004 Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 80 (Suppl 1) 79-84. (doi:10.1159/000080747)
112. O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de HerderWW, Hyrdel R, Nikou G, Krenning E, Vullierme MP et al. 2006a Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84 189-195. (doi:10.1159/ 000098011)
113. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P & Barlier A 2006b The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. European Journal of Endocrinology 155 849-857. (doi:10.1530/eje.1.02307)
114. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR & Muller J 1999 Yttrium-90 DOTATOC: first clinical results. European Journal of Nuclear Medicine 26 1439-1447. (doi:10.1007/s002590050476)
115. Pascher A, Steinmuller T, Radke C, Hosten N, Wiedenmann B, Neuhaus P & Bechstein WO 2000 Primary and secondary hepatic manifestation of neuroendocrine tumors. Langenbeck's Archives of Surgery 385 265-270. (doi:10.1007/s004230000142)
116. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H & Srikant CB 1995 The somatostatin receptor family. Life Sciences 57 1249-1265. (doi:10.1016/0024-3205(95)02082-T)
117. Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J &Poston GJ 2001 (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. European Journal of Surgical Oncology 27 404-408. (doi:10.1053/ejso.2001.1132)
118. Pederzoli P, Falconi M, Bonora A, Salvia R, Sartori N, Contro C, Marcucci S & Bassi C 1999 Cytoreductive surgery in advanced endocrine tumours of the pancreas. Italian Journal of Gastroenterology and Hepatology 31 (Suppl 2) S207-S212. (Pubitemid 29527897)
119. Pfitzmann R, Benscheidt B, Langrehr JM, Schumacher G, Neuhaus R & Neuhaus P 2007 Trends and experiences in liver retransplantation over 15 years. Liver Transplantation 13 248-257. (doi:10.1002/lt.20904)
120. Plockinger U & Wiedenmann B 2007 Neuroendocrine tumors. Biotherapy. Best Practice & Research. Clinical Endocrinology & Metabolism 21 145-162. (doi:10.1016/j.beem.2007.01.002)
121. Que FG, Nagorney DM, Batts KP, Linz LJ & Kvols LK 1995 Hepatic resection for metastatic neuroendocrine carcinomas. American Journal of Surgery 169 36-42. (doi:10.1016/S0002-9610(99)80107-X)
122. Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G & Oberhuber G 2001 Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology 60 141-145. (doi:10.1159/000055311)
123. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R et al. 2005 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54 (Suppl 4) iv1-iv16. (doi:10.1136/gut.2004.053314)
124. Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, Kaltsas G, Kelestimur F, Kvols L, Scoazec JY et al. 2008 Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 87 31-39. (doi:10.1159/000111036)
125. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle
126. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C & Conte PF 2000a Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Annals of Oncology 11 1127-1130. (doi:10.1023/A:1008383132024)
127. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F & Conte PF 2000b Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. American Journal of Clinical Oncology 23 412-415. (Pubitemid 32429157)
128. Ringe B, Lorf T, Dopkens K & Canelo R 2001 Treatment of hepatic metastases from gastroenteropancreatic neuroendocrine tumors: role of liver transplantation. World Journal of Surgery 25 697-699. (doi:10.1007/s00268-001- 0016-5)
129. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
130. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M & Ducreux M 2003 Transcatheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. European Journal of Radiology 13 136-140. (Pubitemid 36790502)
131. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC & Patel YC 2000 Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. Journal of Biological Chemistry 275 7862-7869. (doi:10.1074/jbc.275.11.7862)
132. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP &Boeker KH 2002 Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 73 386-394. (doi:10.1097/00007890-200202150-00012)
133. Roy RC, Carter RF & Wright PD 1987 Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity. Anaesthesia 42 627-632. (doi:10.1111/j.1365-2044.1987.tb03087.x)
134. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P & Anthony L 1999 Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 17 600-606. (Pubitemid 29075248)
135. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R et al. 1996 Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39 279-283. (doi:10.1136/gut.39.2.279)
136. Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B et al. 2004 Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80 244-251. (doi:10.1159/000082875)
137. Ruszniewski P, Delle FG, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H et al. 2006 Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 84 158-164. (doi:10.1159/ 000098007)
138. Saijo F, Naito H, Funayama Y, Fukushima K, Shibata C, Hashimoto A, Kitayama T, Nagao M, Matsuno S &Sasaki I 2003 Octreotide in control of multiple liver metastases from gastrinoma. Journal of Gastroenterology 38 905-908. (doi:10.1007/s00535-002-1170-8)
139. Sarmiento JM & Que FG 2003 Hepatic surgery for metastases from neuroendocrine tumors. Surgical Oncology Clinics of North America 12 231-242. (doi:10.1016/S1055-3207(02)00076-5)
140. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM & Que FG 2003 Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 197 29-37. (doi:10.1016/S1072-7515(03)00230-8)
141. Scherubl H, Wiedenmann B, Riecken EO, Thomas F, Bohme E & Rath U 1994 Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. European Journal of Cancer 30A 1590-1591. (doi:10.1016/0959-8049(94)90065-5)
142. Schmid HA 2008 Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001). Annales d'Endocrinologie 69 162-163. (doi:10.1016/j.ando.2008.02.020)
143. Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C, Wilke H & Weiss J 1992 Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. European Journal of Cancer 28A 1664-1666. (doi:10.1016/0959-8049(92)90064-9)
144. 90Y-DOTATOC. European Journal of Nuclear Medicine and Molecular Imaging 29 435. (doi:10.1007/s00259-001-0720-2)
145. Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A et al. 2010 Treatment with tandem [90Y]DOTA-TATE an [177Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Quarterly Journal of Nuclear Medicine and Molecular Imaging 54 84-91.
146. Siperstein AE & Berber E 2001 Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World Journal of Surgery 25 693-696. (doi:10.1007/s00268-001-0015-6)
147. Skogseid B, Oberg K, Akerstrom G, Eriksson B, Westlin JE, Janson ET, Eklof H, Elvin A, Juhlin C & Rastad J 1998 Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World Journal of Surgery 22 673-677. (doi:10.1007/s002689900451)
148. Smith DB, Scarffe JH, Wagstaff J & Johnston RJ 1987 Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treatment Reports 71 1265-1266.
149. Soga J & Yakuwa Y 1998 Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. Journal of Experimental & Clinical Cancer Research 17 389-400. (Pubitemid 29083408)
150. Solcia E, Capella C, Fiocca R, Rindi G & Rosai J 1990 Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. American Journal of Surgical Pathology 14 503-513. (doi:10.1097/00000478-199006000-00001)
151. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA & Evans DB 2001 Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130 1078-1085. (doi:10.1067/msy.2001.118367)
152. Soreide O, Berstad T, Bakka A, Schrumpf E, Hanssen LE, Engh V, Bergan A & Flatmark A 1992 Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111 48-54.
153. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J et al. 2008 Consensus guidelines for the management of patients with liver metastases from digestive (neuro)-endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 47-62. (doi:10.1159/000111037)
154. Stuart K, Levy DE, Anderson T, Axiotis CA, Dutcher JP, Eisenberg A, Erban JK & Benson AB III 2004 Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Investigational New Drugs 22 75-81. (doi:10.1023/B:DRUG.0000006177.46798.1f)
155. Sun W, Lipsitz S, Catalano P, Mailliard JA & Haller DG 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23 4897-4904. (doi:10.1200/JCO.2005.03.616)
156. Sward C, Johanson V, Nieveen van DE, Jansson S, Nilsson O, Wangberg B, Ahlman H & Kolby L 2009 Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. British Journal of Surgery 96 517-521. (doi:10.1002/bjs.6587)
157. Taylor JE, Bogden AE, Moreau JP & Coy DH 1988 In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochemical and Biophysical Research Communications 153 81-86. (doi:10.1016/S0006-291X(88)81192-6)
158. Thulin L, Samnegard H, Tyden G, Long DH & Efendic S 1978 Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 2 43. (doi:10.1016/S0140-6736(78)91348-X)
159. Tiensuu Janson EM, Ahlstrom H, Andersson T & Oberg KE 1992 Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. European Journal of Cancer 28A 1647-1650. (doi:10.1016/0959-8049(92) 90060-F)
160. Tomassetti P, Migliori M & Gullo L 1998 Slow-release lanreotide treatment in endocrine gastrointestinal tumors. American Journal of Gastroenterology 93 1468-1471. (doi:10.1111/j.1572-0241.1998.465-q.x)
161. Tomassetti P, Migliori M, Corinaldesi R & Gullo L 2000 Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Alimentary Pharmacology & Therapeutics 14 557-560. (doi:10.1046/j.1365-2036.2000.00738. x)
162. Toumpanakis C, Meyer T & Caplin ME 2007a Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Practice & Research. Clinical Endocrinology & Metabolism 21 131-144. (doi:10.1016/j.beem.2007.01.005)
163. Toumpanakis C, Standish RA, Baishnab E, Winslet MC &Caplin ME 2007b Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Diseases of the Colon and Rectum 50 315-322. (doi:10.1007/s10350-006-0762-4)
164. Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J & Caplin ME 2009 Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Alimentary Pharmacology &Therapeutics 30 733-740. (doi:10.1111/j.1365-2036.2009.04083.x)
165. Toumpanakis C, Caplin ME, Quigley AM, Marelli L, Chilkunda D, Khan MS, Meyer T & Buscombe J 2010 90 Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumours. Annals of Oncology 21 (Supplement 6) vil3. (doi:10.1093/annonc/mdq268)
166. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C et al. 2010 Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. British Journal of Cancer 102 1106-1112. (doi:10.1038/sj.bjc.6605618)
167. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, de Herder WW et al. 2002 Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Seminars in Nuclear Medicine 32 110-122. (doi:10.1053/snuc/2002. 31025)
168. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ & Hobday TJ 2006 Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transplantation 12 448-456. (doi:10.1002/lt.20702)
169. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G & Riva P 2002 In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Seminars in Nuclear Medicine 32 148-155. (doi:10.1053/snuc.2002.31565)
170. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A & Mueller-Brand J 2002 Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of Nuclear Medicine 43 610-616. (Pubitemid 34507110)
171. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, Johansson V, Schersten T & Ahlman H 1996 Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World Journal of Surgery 20 892-899. (doi:10.1007/s002689900136)
172. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G &Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581. (Pubitemid 32103642)
173. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG & Oberg KE 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology 17 1111.
174. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, Benson AB, Rao S & Joehl RJ 2001 Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130 677-682. (doi:10.1067/msy.2001.117377)
175. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL & Ajani JA 2008 Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Journal of Clinical Oncology 26 1316-1323. (doi:10.1200/JCO.2007.13.6374)
176. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
177. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
178. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH & Auernhammer CJ 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 54-60. (doi:10.1159/000100057)